LIFILEUCEL
UNII R0835E18NH

Substance Identification & Data

This profile provides standardized clinical and technical data for Lifileucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) R0835E18NH.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2306267-74-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

R0835E18NH

CAS Registry Number

2306267-74-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LIFILEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

R0835E18NH

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C120552

National Cancer Institute reference terminology for clinical and research data.

INN ID

10728

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-69

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lifileucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LIFILEUCEL

Common Names & Synonyms

AN AUTOLOGOUS CD4+ AND CD8+ TUMOR INFILTRATING LYMPHOCYTE, DERIVED FROM ISOLATED METASTATIC MELANOMA CULTURED IN THE PRESENCE OF FEEDER CELLS (IRRADIATED ALLOGENEIC MONONUCLEAR CELLS FROM HEALTHY DONORS), AND HUMAN RECOMBINANT INTERLEUKIN 2/MUROMONAB-CD3 FOR TREATMENT OF METASTATIC MELANOMA

AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES (TIL) DERIVED FROM THE PATIENT'S OWN TUMOR.

HUMAN CULTURE EXPANDED ACTIVATED AUTOLOGOUS T CELLS FOR CELL-BASED IMMUNOTHERAPY. THE CELL SUBSTANCE IS A HETEROGENEOUS MIXTURE CONSISTING OF CD4+ AND CD8+ TUMOR-INFILTRATING LYMPHOCYTES (TIL), DERIVED FROM ISOLATED TUMOR BIOPSY OF PATIENTS WITH MELANOMA OR CERVICAL CARCINOMA, AND CULTURED IN THE PRESENCE OF FEEDER CELLS (IRRADIATED ALLOGENEIC MONONUCLEAR CELLS FROM HEALTHY DONORS) AND HUMAN RECOMBINANT INTERLEUKIN 2 (IL-2)/OKT3 ANTI-CD3 ANTIBODY (MUROMONAB-CD3 (59) (29) FOR T-CELL ACTIVATION

LIFILEUCEL [INN]

LIFILEUCEL [USAN]

LIFILEUCEL [WHO-DD]

LN 145 [WHO-DD]

TUMOR INFILTRATING LYMPHOCYTES, AUTOLOGOUS (FROM MELANOMA TUMORS)